A novel autoantibody test for the detection of pre-neoplastic lung lesions

Abstract

BackgroundAtypical adenomatous hyperplasia (AAH) and squamous cell dysplasia (SCD) are associated with the development of malignant lesions in the lung. Accurate diagnosis of AAH and SCD could facilitate earlier clinical intervention and provide useful information for assessing lung cancer risk in human populations. Detection of AAH and SCD has been achieved by imaging and bronchoscopy clinically, but sensitivity and specificity remain less than satisfactory. We utilized the ability of the immune system to identify lesion specific proteins for detection of AAH and SCD.MethodsAAH and SCD tissue was surgically removed from six patients of Chinese descent (3 AAH and 3 SCD) with corresponding serum samples. Total RNA was extracted from the tissues and a cDNA library was generated and incorporated into a T7 bacteriophage vector. Following enrichment to remove "normal" reactive phages, a total of 200 AAH related and 200 SCD related phage clones were chosen for statistical classifier development and incorporation into a microarray. Microarray slides were tested with an independent double-blinded population consisting of 100 AAH subjects, 100 SCD subjects and 200 healthy control subjects.ResultsSensitivity of 82% and specificity of 70% were achieved in the detection of AAH using a combination of 9 autoantibody biomarkers. Likewise, 86% sensitivity and 78% specificity were achieved in the detection of SCD using a combination of 13 SCD-associated markers. Sequencing analysis identified that most of these 22 autoantibody biomarkers had known malignant associations.ConclusionsBoth diagnostic values showed promising sensitivity and specificity in detection of pre-neoplastic lung lesions. Hence, this technology could be a useful non-invasive tool to assess lung cancer risk in human populations.

Label-free nanoplasmonic sensing of tumor-associate autoantibodies for early diagnosis of colorectal cancer

“…Current efforts in CRC research are directed not only to define specific TAA panels but also to develop efficient and highly sensitive analytical methods capable of detecting TAA autoantibodies in serum with optimum accuracy and reliability [19,20]. Most commonly employed methodologies are based on ELISA or protein microarrays [21] which are usually aimed at finding relative cut-off values, so far providing qualitative or semi-quantitative results.…”

Autoantibodies against heat shock proteins as biomarkers for the diagnosis and prognosis of cancer

“…Using this combination of 9 autoantibodies, the sensitivity and specificity could reach 82% and 70%, respectively. So detecting a combination of AAbs could provide the information for assessing lung cancer risk and could be used for early diagnosis or screening of lung cancer [46]. At last, using immunobead assay and a combination of 6 other autoantibodies including anti-HSP70 autoantibody, NSCLC patients were efficiently discriminated from healthy controls with an observed AUC of 0.934, which have a high potential utility as a diagnostic test [45].…”

Autoantibodies against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia

“…Autoantibodies can be observed in the sera of patients with solid tumors and hematological malignancies [ 4 , 5 ]. These autoantibodies are regarded as early biomarkers for some types of cancer [ 6 , 7 , 8 ].…”